The justices have asked for the solicitor general’s views on a cert petition by Amgen in a case that could reinterpret patent law’s Section 112 and the law of enablement.
With Billions at Stake, Supreme Court Dips Its Toes Into Biologic Drug Patents
Leave a Reply